Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$6.36 - $11.47 $514,008 - $926,993
-80,819 Reduced 33.75%
158,647 $1.31 Million
Q1 2023

May 15, 2023

SELL
$7.03 - $11.53 $1 Million - $1.65 Million
-142,882 Reduced 37.37%
239,466 $1.74 Million
Q4 2022

Feb 13, 2023

SELL
$8.32 - $13.21 $936,016 - $1.49 Million
-112,502 Reduced 22.73%
382,348 $3.39 Million
Q3 2022

Nov 14, 2022

BUY
$12.16 - $19.42 $1.41 Million - $2.26 Million
116,188 Added 30.68%
494,850 $6.06 Billion
Q2 2022

Aug 12, 2022

BUY
$9.99 - $21.35 $111,428 - $238,137
11,154 Added 3.04%
378,662 $4.48 Million
Q1 2022

May 12, 2022

BUY
$14.08 - $27.63 $1.63 Million - $3.2 Million
115,802 Added 46.01%
367,508 $6.99 Million
Q4 2021

Feb 10, 2022

BUY
$26.55 - $40.57 $6.31 Million - $9.64 Million
237,492 Added 1670.83%
251,706 $6.68 Million
Q3 2021

Nov 12, 2021

SELL
$39.27 - $72.94 $77,636 - $144,202
-1,977 Reduced 12.21%
14,214 $583,000
Q2 2021

Aug 12, 2021

BUY
$31.29 - $56.64 $506,616 - $917,058
16,191 New
16,191 $917,000
Q4 2020

Feb 12, 2021

SELL
$27.07 - $84.35 $870,733 - $2.71 Million
-32,166 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$28.06 - $37.16 $902,577 - $1.2 Million
32,166 New
32,166 $902,000
Q1 2020

May 13, 2020

SELL
$14.88 - $32.78 $194,734 - $428,991
-13,087 Closed
0 $0
Q4 2019

Feb 13, 2020

SELL
$19.49 - $32.63 $1.09 Million - $1.82 Million
-55,825 Reduced 81.01%
13,087 $388,000
Q4 2018

Feb 13, 2019

BUY
$18.19 - $31.79 $786,535 - $1.37 Million
43,240 Added 168.43%
68,912 $1.57 Million
Q3 2018

Nov 14, 2018

BUY
$27.65 - $38.39 $709,830 - $985,548
25,672 New
25,672 $817,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $92.1M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Capital Fund Management S.A. Portfolio

Follow Capital Fund Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Capital Fund Management S.A. with notifications on news.